Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX15-SC + lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
HLX15-SC + lenalidomide + dexamethasone is a combination therapy being developed by Shanghai Henlius Biotech for the treatment of multiple myeloma. HLX15-SC is a subcutaneous formulation of a daratumumab biosimilar, a fully human IgG1κ monoclonal antibody that targets CD38, a protein highly expressed on multiple myeloma cells. The mechanism of action for HLX15-SC involves binding to CD38 and inducing tumor cell death through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). This combination, often referred to as the Rd regimen when paired with the immunomodulatory drug lenalidomide and the corticosteroid dexamethasone, is currently being evaluated in Phase I clinical trials. The study specifically focuses on transplant-ineligible patients with newly diagnosed multiple myeloma to compare the pharmacokinetics, safety, and efficacy of the HLX15-SC-Rd regimen against the reference product Darzalex Faspro in combination with Rd.
- Brand names
- DarzalexRevlimid
- Other names
- HLX15-SC + Rddaratumumab biosimilar (HLX15-SC) + lenalidomide + dexamethasone
02
Targets
GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)
Beyond the preview
Go deeper on HLX15-SC + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX15-SC + lenalidomide + dexamethasone.